A robust neuro-centric Pipeline
for diseases with high unmet medical need
PIPELINE
ASHA-091
Mitochondria Quality Control in Neurological Diseases
The dysregulation of mitochondrial dynamics, can lead to the hyper-fragmentation of mitochondria driven by activation of DRP1, and are common pathological contributors to a host of neurological diseases ranging from neurodegenerative diseases such as Parkinson's Disease and Alzheimer's Disease to neurovascular ischemia and stroke, as well as post-viral neuropathologies including Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long Haul COVID.
ASHA-091 has been designed to specifcally inhibit fragmentation and restore normal mitochondrial dynamics. ASHA-091 is a near clinic-ready, first-in-class, orally bioavailable, disease modifying brain-penetrant inhibitor of DRP1 with multiple disease indications.
Axons are key nerve fibers that carry signals between neurons within the brain. These axons become damaged, leading to neuronal dysfunction and neuronal loss in multiple neurodegenerative diseases. We are focused on exploiting basic neuron biology to create novel compounds
for treating diseases including Amyotrophic Lateral Sclerosis (ALS), Spinal Cord & Traumatic Brain Injury, and Multiple System Atrophy (MSA).
ASHA-624 has been created using the PRISM™ platform and Asha's proprietary, novel molecular glue technology. Targeting a key protein involved in regulating axonal degeneration, ASHA-624 prevents axon loss and preserves neurological function. Preclinical evaluation in ALS, SCI/TBI, and MSA is ongoing.
ASHA-624
Combating Axonal Degeneration
& Neuronal Demise
Asha's proprietary molecular glue technology allows for the transient and reversible alteration of target protein structure as well as target protein interactions. The transient aspect of our molecular glues compounds allows for the first-in-class reversible modulation of protein targets. This on/off capability ensures that compounds including ASHA-624 are capable of restoring normal physiology while mitigating permanent or off target sequelae.
ASHA-624 has multiple disease indications in both the central and peripheral nervous systems. Use of ASHA-624 beyond our focused indications has the potential to be beneficial in the future based on published studies showing a high association between ASHA-624's target and neuropathology.
